Bracing for Impact: The Future of Hub, PAP, and Affordability Programs Under the Inflation Reduction Act

What does the IRA mean for you and your patients?

With the Inflation Reduction Act (IRA) introducing significant reforms to prescription drug pricing, including mandatory price negotiations and penalties for price increases exceeding inflation, pharmaceutical companies face substantial revenue and profitability challenges. But these hurdles highlight the importance of maintaining patient-centric support amidst budget reductions, emphasizing the need for brand leaders to adapt their strategies to ensure continued access and affordability for patients.

Join us as we outline both the continuity and evolution expected in patient support programs, and offer practical adjustments your brand can implement to "do more with less money" while safeguarding patient welfare.